Selective PI3Kδ inhibitors, a review of the patent literature

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.11, 2011-11, pp. : 1773-1790

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 965-970

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 971-976

Informa Healthcare

Access to resources Recommend Favorite

Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1805-1810

Informa Healthcare

Access to resources Recommend Favorite

Antiobesity carbonic anhydrase inhibitors: a literature and patent review

By Scozzafava Andrea Supuran Claudiu T Carta Fabrizio

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 6, 2013-06 ,pp. : 725-735

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of PDE4: a review of recent patent literature

By Odingo Joshua O

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 7, 2005-07 ,pp. : 773-787

Informa Healthcare

Access to resources Recommend Favorite